ACRUX LIMITED
ASX:ACRPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 67.4% of what they think they own, once every option and right converts.
Share count grew 108% in 24 months; options/rights overhang 48% of shares; 1 cash raise in 24 months
ACRUX LIMITED had 606M ordinary shares outstanding as of August 2026, according to the ASX market reading. A share count change figure is not stated for the 24-month period as the Appendix 2A series finishes earlier than the latest reported share count date. The company conducted one capital raise in the past 24 months, a placement in May 2026 that brought in A$1.6M. There are potential new shares of 293M from options and rights, representing 48.3% of the current share count, with the nearest expiry in February 2027. None of these are currently in the money. As of June 2026, ACRUX LIMITED had A$4.1M in cash. A funding-runway figure does not apply as the company reported non-negative net cash flow for the latest quarter. No proposed securities issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 2 Sept 2026 | 2A · quoted issue | ACR : ORDINARY FULLY PAID | 605.6M | Appendix 2A |
| 2 Sept 2026 | 2A · quoted issue | ACR : ORDINARY FULLY PAID | 590.6M | Appendix 2A |
| 12 Aug 2026 | 3H · cancellation | ACR : ORDINARY FULLY PAID | 589.7M | Appendix 3H |
| 12 Aug 2026 | 2A · quoted issue | ACR : ORDINARY FULLY PAID | 589.9M | Appendix 2A |
| 29 July 2026 | 3G · unquoted | ACR : ORDINARY FULLY PAID | 523.9M | Appendix 3G |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (605.6M) need not equal the current count above (606.3M).
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered278.9M · 46.0% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 168.5M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered14.1M · 2.3% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 110.4M priced, 182.6M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
An exercise price is on record for only 37.7% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.011 today. At double today’s price it is 110.4M (18.2% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 182.6M (62.3% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ACRO | Options | Price-triggered | — | 19 Feb 2027 | 160.5M | Filing |
| ACRAC | Options | Price-triggered | $0.018 | 29 July 2030 | 110.4M | Filing |
| ACRAU | Options | Price-triggered | — | 1 June 2032 | 8.0M | Filing |
| ACRAT | Performance rights | Condition-triggered | — | — | 14.1M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 3 Sept 2026 | Don Brumley | Other | 2.4M | — | 717k | — | 3Y notice |
| 3 Sept 2026 | Geoffrey Brooke | Other | 2.4M | 286k | — | — | 3Y notice |
| 3 Sept 2026 | John Warmbrunn | Other | 3.8M | 8.0M | — | — | 3Y notice |
| 3 Sept 2026 | Ross Dobinson | Other | 4.8M | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.